PharmX Technologies (ASX:PHX) Total Long-Term Assets: A$12.78 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PHX PharmX Technologies Ltd ASX:PHX
35 GF Score
Price A$0.11
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Total Long-Term Assets?

PharmX Technologies ASX:PHX -2.22% 35 Total Long-Term Assets is A$12.78 Mil as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 35/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. PharmX Technologies's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$12.78 Mil.

PharmX Technologies Total Long-Term Assets Related Terms

PharmX Technologies Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Total Long-Term Assets Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.93 22.18 13.93 13.49 13.07

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.78 13.49 12.30 13.07 12.78
ASX:PHX
35GF Score
PharmX Technologies Ltd ASX:PHX
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmX Technologies Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$12.78 Mil mean?
PharmX Technologies (ASX:PHX) has a Total Long-Term Assets of A$12.78 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Total Long-Term Assets too high?
PharmX Technologies' current Total Long-Term Assets is A$12.78 Mil. Overall, PharmX Technologies has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Total Long-Term Assets compare to VEEV and BTSG?
PharmX Technologies' Total Long-Term Assets of A$12.78 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Healthcare Providers & Services company?
A good Total Long-Term Assets depends on the Healthcare Providers & Services industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Total Long-Term Assets is A$12.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.11 — trading 57.1% above its estimated fair value. The current Total Long-Term Assets is A$12.78 Mil. PharmX Technologies' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Total Long-Term Assets is A$12.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.11 is trading 57.1% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Total Long-Term Assets: A$12.78 Mil
  • GF Value™: A$0.07 vs. price of A$0.11 (57.1% above fair value)
  • GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
35GF Score

Get the complete analysis for ASX:PHX

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.07
GF Value